Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. Actinium is developing innovative targeted radiotherapies for the treatment of advanced cancers.

Oral Presentation recap: new data on ATNM-400 in prostate cancer demonstrated ATNM-400 remains potently active in pros...
06/03/2026

Oral Presentation recap: new data on ATNM-400 in prostate cancer demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor pathway inhibitors (ARPIs), directly targeting the point of failure for a high proportion of mCRPC patients.

The data also demonstrated activity as both a monotherapy and in combination with approved ARPIs, supporting continued development of ATNM-400 in prostate cancer.

Read more: https://bit.ly/4fY71yU

Recap: Actinium Pharmaceuticals shared new data on ATNM-400 in KRAS and EGFR-mutant NSCLC models.The new KRAS-mutant d...
06/03/2026

Recap: Actinium Pharmaceuticals shared new data on ATNM-400 in KRAS and EGFR-mutant NSCLC models.

The new KRAS-mutant data, together with a growing body of EGFR-mutant data, demonstrate ATNM-400's activity across the two major mutation driver classes in NSCLC and support a distinct strategic opportunity.

ATNM-400 can be developed as a potential mutation-agnostic backbone for the broader NSCLC market, alone or in combination with standard-of-care therapies, rather than as another mutation-specific drug for a narrow subset.

Read the press release to learn more: https://bit.ly/4397fvE

Society of Nuclear Medicine and Molecular Imaging

Actinium is pleased to welcome Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination o...
06/01/2026

Actinium is pleased to welcome Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company experience.

His appointment comes at a pivotal moment as Actinium prepares to advance Actimab-A, ATNM-400, and Iomab-ACT toward key data readouts and expanded clinical trials in the second half of 2026.

Welcome to the team!

Read more: https://bit.ly/4ucmSgF

Actinium will present new ATNM-400 prostate cancer data at , demonstrating activity across PSMA-high, PSMA-low and PSMA...
05/29/2026

Actinium will present new ATNM-400 prostate cancer data at , demonstrating activity across PSMA-high, PSMA-low and PSMA-negative disease.

The data further supports ATNM-400’s differentiated profile and potential applicability beyond limitations associated with PSMA-targeted therapies.

Presentation details:

Tuesday, June 2, 2026
11:30 am–12:15 pm PT
Oncology: Discovery & Translational Meet the Author Session

Read more: https://bit.ly/4dM5RoH

Actinium will present ATNM-400 data in non-small cell lung cancer at , demonstrating durable, mutation-agnostic anti-tu...
05/27/2026

Actinium will present ATNM-400 data in non-small cell lung cancer at , demonstrating durable, mutation-agnostic anti-tumor activity in KRAS-mutated models.

The findings support ATNM-400’s potential in settings where resistance to EGFR- and KRAS-targeted therapies remains a major clinical challenge.

Presentation details:

Tuesday, June 2, 2026
11:30 am–12:15 pm PT
Oncology: Discovery & Translational Meet the Author Session

More info: https://bit.ly/4dM5RoH

Actinium will present preclinical radioconjugation data at , demonstrating that optimization of chelator-to-antibody ra...
05/25/2026

Actinium will present preclinical radioconjugation data at , demonstrating that optimization of chelator-to-antibody ratio improves tumor targeting, internalization and pharmacokinetics of 225Ac-labeled antibodies.

The findings directly support ATNM-400 development and reinforce Actinium’s radiochemistry platform supporting next-generation targeted radiotherapies.

Presentation details:

Sunday, May 31, 2026
7:30–8:00 pm PT
MTA05 RPSC/CMIIT POPs and Science Pavilion Mixer

More info: https://bit.ly/4dM5RoH

Next week at , Actinium will present a set of three abstracts spanning ATNM-400 solid tumor research and radioconjugati...
05/22/2026

Next week at , Actinium will present a set of three abstracts spanning ATNM-400 solid tumor research and radioconjugation optimization science.

The data cover preclinical findings in non-small cell lung cancer and prostate cancer, along with antibody engineering work designed to improve the behavior and performance of 225Ac-labeled therapies.

The presentations reflect parallel progress in tumor biology and radiopharmaceutical design within Actinium’s pipeline.

May 30–June 2, 2026 | Los Angeles, California

At , Actinium will present three abstracts featuring ATNM-400 across lung and prostate cancer, along with data supporti...
05/20/2026

At , Actinium will present three abstracts featuring ATNM-400 across lung and prostate cancer, along with data supporting its radioconjugate optimization platform.

The data reinforce ATNM-400’s potential as a differentiated targeted radiotherapy across multiple solid tumor settings.

Dates: May 30–June 2, 2026
Location: Los Angeles, California

Details: https://bit.ly/4dM5RoH

ICYMI: Actinium announced three upcoming presentations at , May 30–June 2, 2026, in Los Angeles, California, highlighti...
05/18/2026

ICYMI: Actinium announced three upcoming presentations at , May 30–June 2, 2026, in Los Angeles, California, highlighting the differentiated profile of ATNM-400 across NSCLC and prostate cancer, along with radioconjugate optimization supporting its development.

New data demonstrates mutation-agnostic anti-tumor activity in KRAS-mutated NSCLC models, activity across PSMA-high, low and negative prostate cancer disease, and improved tumor targeting and pharmacokinetics through optimization of chelator-to-antibody ratio.

Presentation dates:
• May 31, 2026 | 7:30–8:00 pm PT
• June 2, 2026 | 11:30 am–12:15 pm PT

Read more: https://bit.ly/4dM5RoH

Address

275 Madison Avenue, 7th Floor
New York, NY
10016

Website

Alerts

Be the first to know and let us send you an email when Actinium Pharmaceuticals, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Actinium Pharmaceuticals, Inc.:

Shortcuts

Share

Category